Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of therapeutic dose intravenous
heparin at improving replantation/revascularization success and its indications (if any) in
participants who have suffered traumatic digital amputation. Digital
replantation/revascularization success will be assessed in participants who receive
continuous intravenous drip of thromboprophylactic heparin at a therapeutic dose (i.e.
modifies INR to the desired range) contrasted to those who do not receive therapeutic dose
heparin (i.e. does not modify INR to the desired range). In the study,
replantation/revascularization success is defined as a clearly viable digit at the time of
discharge. Secondary objectives include assessing postoperative complications associated with
heparin use, such as bleeding, hematoma or heparin induced thrombocytopenia. The
investigators would also assess the impact of categorical variables such as smoking status,
mechanism of injury and comorbidities, on digital survival.